🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🗓️Join us May 20 for a conversation with Nobel Laureate Daniel McFadden about his groundbreaking work on the science behind human decision-making. Co-hosted w/Intl Academy of Health Preference Research, PREFER: patient preferences, International Health Economics Association (IHEA) Health Preference SIG and Erasmus Choice Modelling Centre (ECMC). schaeffer.usc.edu/event/revoluti…

Researchers are calling it the Diabetes Paradox. While advances in treatment & diagnosis mean fewer health complications for people with #diabetes, workforce participation & disability claims haven't improved, finds Schaeffer research in JAMA Health Forum. schaeffer.usc.edu/research/diabe…

Lowering drug prices to European benchmarks would ultimately shrink innovation and make Americans less healthy, Schaeffer Scholars write in STAT. Instead, a drug pricing system based on U.S. values would enhance access and support medical progress. schaeffer.usc.edu/research/ensur…

In a candid exchange with Senator John Kennedy during the Senate Judiciary Committee hearing, #USCPrice Professor and USC Schaeffer Senior Scholar Neeraj Sood laid out three actionable steps to lower drug costs: price transparency, fiduciary responsibility for pharmacy benefit

Expanded coverage of GLP-1s, which have proven incredibly effective at inducing weight loss in people with obesity, is “probably the single most effective policy” for improving public health, says #USCSchaeffer Director Dana Goldman.

U.S. drug launch prices are rising as more and more powerful new treatments for rare diseases reach the market. Schaeffer Scholar Bill Padula, PhD discusses the costs and benefits of innovation with Reuters. reuters.com/business/healt…

Implementation of the IRA's drug pricing provisions could threaten Americans' health and U.S. leadership in biomedical innovation, Schaeffer Center Co-Director Erin Trish warned lawmakers in testimony this week. Trish's testimony👇schaeffer.usc.edu/research/testi…

Clinical trials for #Alzheimers are typically much slower than in other therapeutic areas. The FDA’s first approval of a blood test to help detect the disease holds enormous potential to accelerate research. schaeffer.usc.edu/research/alzhe…

Compounding pharmacies are selling custom versions of GLP-1s to avoid a government crackdown on weight-loss drug knockoffs. But lots of companies are “pushing the envelope" on what's allowed, Schaeffer Nonresident Senior Scholar Lowell Schiller tells The Wall Street Journal. wsj.com/health/pharma/…

📽️New Video: USC Schaeffer Distinguished Scholar Daniel McFadden reflects on the evolution of his #NobelPrize-winning work in discrete choice modeling and what's next for decision science. youtube.com/watch?v=f2-5o5…

📢 Funding opportunity: The Clinical Trial Recruitment Lab is inviting applications for projects leveraging innovative tech-based approaches, including AI and machine learning, to overcome recruitment & retention barriers in #Alzheimers clinical trials. schaeffer.usc.edu/research/2025-…

In his new Forefront article, Jonathan Blum from USC Schaeffer discusses how, as a result of Secretary Kennedy’s recently announced cuts, CMS will have fewer staff on board than it did in 2015, despite overseeing a budget almost twice as large, serving millions more people, and

New Schaeffer Center white paper finds targeted tax policies like tariffs or R&D credits do little to stimulate biomedical innovation. Instead, reducing corporate tax rates is key to supporting U.S. leadership in this critical area. schaeffer.usc.edu/research/biome…

California hospital spending on supplemental payments to contracted medical groups has steadily grown in key specialties over the past two decades, Schaeffer Scholar Erin Duffy finds in a Health Affairs study. schaeffer.usc.edu/research/hospi…

"Upcoding" patient diagnoses led to an estimated $50 billion in #MedicareAdvantage overpayments last year. Schaeffer Scholars Paul Ginsburg and Steve Lieberman in Health Affairs Forefront detail a two-part strategy for reining in the practice. healthaffairs.org/content/forefr…

"The more you see how #PBMs have evolved and the games they play, the more you just get pessimistic that this little piecemeal legislation at the state level is going to do anything to them," said #USCSchaeffer Senior Scholar Geoffrey Joyce.

Medicare’s Coverage with Evidence Development program was meant to speed patient access to innovative treatments, but it’s instead become an unnecessary hurdle in need of major reform, Sr. Scholar Joe Grogan writes in the The Wall Street Journal. wsj.com/opinion/agency…

Schaeffer's Genevieve Kanter, PhD discusses w/Reuters her upcoming research finding that declared conflicts of interest on CDC's vaccine advisory panel had declined significantly in recent years. reuters.com/business/healt…

If RFK Jr. wants to “clean up the corruption and conflicts” at HHS, he is going about it the wrong way, writes Senior Scholar Genevieve Kanter, PhD in STAT. statnews.com/2025/06/12/rfk…

USC's Clinical Trial Recruitment Lab, our partnership with Alzheimer's Therapeutic Research Institute, recently convened 40 leading experts to address an urgent question: How do we accelerate recruitment of a more representative population in #Alzheimers trials? The key takeaways ⬇️ schaeffer.usc.edu/research/advan…